High affinity immunoglobulin epsilon receptor-IgE-Dermatophagoides farinae allergen complex (FcεRI-IgE-Der f complex)

The High affinity immunoglobulin epsilon receptor-IgE-Dermatophagoides farinae allergen complex is the primary molecular driver of Type I hypersensitivity reactions in individuals sensitized to house dust mites. This complex forms when Dermatophagoides farinae allergens, such as Der f 1 or Der f 2, cross-link IgE antibodies that are already bound to the alpha subunit of the FcεRI receptor on the surface of mast cells and basophils [Galli & Tsai, 2012, Nature Medicine, https://pubmed.ncbi.nlm.nih.gov/22561833/]. This cross-linking event triggers an intracellular signaling cascade involving Lyn and Syk kinases, ultimately leading to the rapid degranulation of the cell and the release of inflammatory mediators like histamine and proteoglycans [UniProt P12319, https://www.uniprot.org/uniprotkb/P12319/entry]. These mediators are responsible for the clinical symptoms of allergic rhinitis, bronchial asthma, and atopic dermatitis [Thomas et al., 2002, Allergy, https://pubmed.ncbi.nlm.nih.gov/12144551/]. Therapeutic interventions targeting this complex focus on either preventing its formation or modulating the immune response to the allergen. Omalizumab is a monoclonal antibody that binds to the Fc region of free IgE, preventing it from interacting with the FcεRI receptor and thereby reducing the density of IgE-receptor complexes on effector cells [FDA Xolair Label, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf]. Alternatively, allergen-specific immunotherapy (AIT), such as the sublingual tablet Odactra, involves controlled exposure to Der f allergens to induce immunological tolerance and shift the immune response away from the IgE-mediated pathway [FDA Odactra Label, https://www.fda.gov/vaccines-blood-biologics/allergenics/odactra]. Monitoring this target often involves measuring allergen-specific IgE levels or utilizing the basophil activation test to assess the functional sensitivity of the patient's effector cells to house dust mite extracts.

Other names

IgE-FcεRI-Der f complexHouse dust mite allergen-IgE-receptor complexMast cell IgE-allergen assemblyDer f-IgE-FcεRI signaling complex

Inhibition of IgE binding to FcεRI, neutralization of free IgE, or desensitization through allergen-specific immunotherapy.